BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

@article{Robinson2000BMS232632AH,
  title={BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.},
  author={Brett S Robinson and Keith A Riccardi and Y F Gong and Qiongjie Guo and David A. Stock and Wade S. Blair and Brian J. Terry and Carol Deminie and F Djang and R. J. Colonno and P F Lin},
  journal={Antimicrobial agents and chemotherapy},
  year={2000},
  volume={44 8},
  pages={
          2093-9
        }
}
BMS-232632 is an azapeptide human immunodeficiency virus type 1 (HIV-1) protease (Prt) inhibitor that exhibits potent anti-HIV activity with a 50% effective concentration (EC(50)) of 2.6 to 5.3 nM and an EC(90) of 9 to 15 nM in cell culture. Proof-of-principle studies indicate that BMS-232632 blocks the cleavage of viral precursor proteins in HIV-infected cells, proving that it functions as an HIV Prt inhibitor. Comparative studies showed that BMS-232632 is generally more potent than the five… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 64 CITATIONS, ESTIMATED 44% COVERAGE

Atazanavir: in pediatric patients with HIV-1 infection.

  • Paediatric drugs
  • 2012
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Molecular Basis for Drug Resistance in HIV-1 Protease

VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Atazanavir: a new protease inhibitor to treat HIV infection.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2004
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2002
2018

CITATION STATISTICS

  • 9 Highly Influenced Citations